莱沃多巴诱导的运动障碍会改变帕金森病患者的姿势控制
Joseph Ayotunde Aderonmu1, Carolin Curtze1
1Department of Biomechanics, University of Nebraska at Omaha, Omaha, NE, United States.
Journal of biomechanics
|November 28, 2024
概括
在帕金森病 (PD) 中,Levodopa诱导的运动障碍 (LID) 会改变姿势摇摆策略,增加头部不稳定性. 这项研究揭示了LID如何影响平衡控制,特别是在药物活性或认知任务期间.
科学领域:
- 神经科学是一个神经科学.
- 生物医学工程 生物医学工程
- 运动学 运动学
背景情况:
- 利沃多巴是帕金森病 (PD) 的首要治疗方法,但长期使用会导致利沃多巴诱导的运动障碍 (LID).
- LID的特点是非自愿的运动,并且已知会影响姿势摇摆.
- LID对姿势摇摆策略的具体影响仍未得到充分研究.
研究的目的:
- 为了研究多巴诱导的运动障碍 (LID) 如何改变帕金森病 (PD) 患者的姿势摇摆策略.
- 为了比较PD患者的姿势控制,有或没有LID,以及健康的老年人.
- 检查药物状态 (ON/OFF) 和认知双重任务对患有LID的PD摇摆策略的影响.
主要方法:
- 招募了25名特异性PD患者 (13名LID) 和10名健康的老年人.
- 在单任务和双任务站立时,使用腰部,干部和头部的惯性传感器测量姿势摆动.
- 计算了摇摆比率,以分析头部,干部和腰部部分对整体摇摆的贡献.
主要成果:
- 与对照组相比,患有LID的参与者表现出明显更大的RMS头部摇摆.
- 在患有LID的PD患者中,头对干部和头对腰部摇摆比率升高,特别是在服用ON状态和双重任务的药物时.
- 患有LID的PD患者表现出多链接摆动模式,与没有LID和健康成年人的PD不同.
结论:
- 莱沃多巴诱导的运动障碍在帕金森病中显著改变了姿势控制策略,导致头部摇和不稳定性增加.
- 患有LID的PD患者采用不同的摇摆策略,特别是在药物活性或认知负载期间.
- 这些发现强调了在评估帕金森病患者的姿势摆动时考虑LID的重要性.
相关概念视频
01:24Parkinson's Disease: Treatment
220
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
220
01:15Parkinson's Disease: Overview
482
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
482
01:37Neural Regulation
39.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.1K
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
259
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
259